Video

Kate Dawson: The Future Looks Bright For Multiple Sclerosis Treatment for Biogen

Author(s):

With multiple medications approved to treat multiple sclerosis there is more work being done to help a larger patient population through the course of disease treatment.

With multiple medications approved to treat multiple sclerosis there is more work being done to help a larger patient population through the course of disease treatment.

While there is work being done to develop new treatments, Kate Dawson, MD, from Biogen said the company is working on new potential treatment methods in addition to finding new applications for its medications on the market today. Dawson, speaking at the annual ECTRIMS meeting in London said they are looking specifically at remylination in addition to other potential alternatives.

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.